SpaceX IPO Hype Doesn't Erase Rocket Lab's Execution Risks

What happened

A new Motley Fool article argues that SpaceX's initial public offering should not lead investors to abandon Rocket Lab, pointing to the company's growing backlog, launch contracts, and defense work as solid growth catalysts. While Rocket Lab indeed has real operating momentum—Q1 2026 revenue up 63% to $200.3 million and a $2.22 billion backlog—the DeepValue master report maintains a WAIT rating, noting that the stock at $100.5 already prices in smooth backlog conversion, credible Neutron timing, and manageable Iridium financing before those assumptions are proven. The report flags three critical near-term proof points: Q2 2026 results must meet guidance of $225M-$240M revenue and 33%-35% gross margin, Neutron must demonstrate tangible milestones toward its Q4 2026 first launch, and Iridium transaction financing must not force dilutive terms. Until these conditions are confirmed, the stock lacks a margin of safety despite the favorable narrative shift.

Implication

Investors should wait for Q2 earnings and visible Neutron milestone progress before considering entry. An attractive entry is around $75, while the stock should be trimmed above $120. The thesis hinges on whether Rocket Lab can convert its backlog into cash flow and avoid further dilution from Iridium financing.

Thesis delta

No material shift. The article reinforces the existing bull case that Rocket Lab is a credible standalone platform, but the master report's caution remains justified given the execution-sensitive valuation. The key risk factors—Neutron timeline, Iridium financing terms, and cash conversion—are unchanged. The next catalyst is Q2 2026 results, which will test whether the company can deliver on guidance.